K-ras point mutations in endometrial carcinoma: effect on outcome is dependent on age of patient

Gynecol Oncol. 1996 Nov;63(2):238-46. doi: 10.1006/gyno.1996.0313.

Abstract

Mutations involving the K-ras proto-oncogene are believed to play an important role in the mechanism of tumorigenesis for many human cancers and occur in 10-30% of endometrial carcinomas. In the present study 221 cases of endometrioid endometrial carcinoma obtained from Japanese patients with average follow-up of 41 months were examined for point mutations in codon 12 of K-ras through use of the polymerase chain reaction. In 103 cases lymph node dissection had been performed. K-ras mutations were significantly associated with the presence of lymph node metastases (P < 0.04). Since endometrial carcinoma in premenopausal women generally behaves less aggressively than tumors of similar histologic grade arising in postmenopausal patients, we evaluated the effect of K-ras mutation on outcome in patients stratified into three different age categories (<53 years, premenopausal; 54-59 years, perimenopausal; >60 years, postmenopausal). In the postmenopausal age group (>60 years), the presence of K-ras mutations was statistically significantly associated with patients who died or experienced recurrence (41.2% vs 13.0%; P < 0.03). This was related to a dramatic (greater than eightfold; P = 0.011) increase in the likelihood of adverse outcome between the premenopausal and postmenopausal states for patients whose tumors contained mutant K-ras. These findings point to a possible role for K-ras activation in the mechanism(s) responsible for more aggressive clinical behavior of endometrioid endometrial cancer that is observed in postmenopausal patients.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • Carcinoma, Endometrioid / genetics*
  • Carcinoma, Endometrioid / pathology
  • Codon / genetics*
  • Disease-Free Survival
  • Endometrial Neoplasms / genetics*
  • Endometrial Neoplasms / pathology
  • Endometrial Neoplasms / secondary
  • Female
  • Genes, ras / genetics*
  • Humans
  • Lymphatic Metastasis
  • Middle Aged
  • Point Mutation*
  • Polymerase Chain Reaction / methods
  • Prognosis
  • Proportional Hazards Models
  • Proto-Oncogene Mas

Substances

  • Codon
  • MAS1 protein, human
  • Proto-Oncogene Mas